| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/06/2024 | 22:01 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:GOSS | Gossamer Bio Inc |
| 07/06/2024 | 22:30 | Business Wire | Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:GOSS | Gossamer Bio Inc |
| 07/06/2024 | 03:58 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:GOSS | Gossamer Bio Inc |
| 14/05/2024 | 22:01 | Business Wire | Gossamer Bio to Provide Updated Seralutinib TORREY Open-Label Extension Data at the American Thoracic Society 2024 International Conference | NASDAQ:GOSS | Gossamer Bio Inc |
| 07/05/2024 | 22:01 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:GOSS | Gossamer Bio Inc |
| 07/05/2024 | 22:01 | Business Wire | Gossamer Bio Announces First Quarter 2024 Financial Results and Provides Business Update | NASDAQ:GOSS | Gossamer Bio Inc |
| 06/05/2024 | 13:30 | Business Wire | Gossamer Bio and Chiesi Group Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in PAH, PH-ILD & Other Indications | NASDAQ:GOSS | Gossamer Bio Inc |
| 03/05/2024 | 14:02 | Business Wire | Gossamer Bio Announces Publication of TORREY Phase 2 Results in the Lancet Respiratory Medicine | NASDAQ:GOSS | Gossamer Bio Inc |
| 12/03/2024 | 12:31 | Business Wire | Gossamer Bio Announces Appointment of Steven D. Nathan, M.D., and Skye Drynan to its Board of Directors | NASDAQ:GOSS | Gossamer Bio Inc |
| 05/03/2024 | 13:37 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:GOSS | Gossamer Bio Inc |
| 05/03/2024 | 13:32 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:GOSS | Gossamer Bio Inc |
| 05/03/2024 | 13:31 | Business Wire | Gossamer Bio Announces Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update | NASDAQ:GOSS | Gossamer Bio Inc |
| 13/12/2023 | 22:01 | Business Wire | Gossamer Bio to Host Webcast to Discuss Latest Seralutinib Open-Label Extension Data on December 18, 2023 | NASDAQ:GOSS | Gossamer Bio Inc |
| 05/12/2023 | 23:09 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:GOSS | Gossamer Bio Inc |
| 05/12/2023 | 13:01 | Business Wire | Gossamer Bio Appoints Bob Smith as Chief Commercial Officer | NASDAQ:GOSS | Gossamer Bio Inc |
| 29/11/2023 | 13:01 | Business Wire | Gossamer Bio Announces Appointment of John Quisel, J.D., Ph.D., to its Board of Directors | NASDAQ:GOSS | Gossamer Bio Inc |
| 09/11/2023 | 13:31 | Business Wire | Gossamer Bio Announces Third Quarter 2023 Financial Results and Provides Business Update | NASDAQ:GOSS | Gossamer Bio Inc |
| 03/10/2023 | 22:08 | Business Wire | Gossamer Bio Announces Addition of Rainer Zimmermann, MD, as VP of Medical Affairs | NASDAQ:GOSS | Gossamer Bio Inc |
| 07/09/2023 | 13:44 | Business Wire | Gossamer Bio to Present Results of TORREY FRI Sub-Study at the European Respiratory Society International Congress 2023 | NASDAQ:GOSS | Gossamer Bio Inc |
| 29/08/2023 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:GOSS | Gossamer Bio Inc |
| 28/08/2023 | 22:29 | Edgar (US Regulatory) | Form 424B3 - Prospectus [Rule 424(b)(3)] | NASDAQ:GOSS | Gossamer Bio Inc |
| 21/08/2023 | 22:01 | Edgar (US Regulatory) | Form DEL AM - Delaying amendment | NASDAQ:GOSS | Gossamer Bio Inc |
| 18/08/2023 | 14:41 | Edgar (US Regulatory) | Form S-3 - Registration statement under Securities Act of 1933 | NASDAQ:GOSS | Gossamer Bio Inc |
| 18/08/2023 | 14:38 | Edgar (US Regulatory) | Form RW - Registration Withdrawal Request | NASDAQ:GOSS | Gossamer Bio Inc |
| 17/08/2023 | 22:01 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:GOSS | Gossamer Bio Inc |
| 08/08/2023 | 22:01 | Business Wire | Gossamer Bio Announces Second Quarter 2023 Financial Results and Provides Business Update | NASDAQ:GOSS | Gossamer Bio Inc |
| 07/08/2023 | 22:44 | Edgar (US Regulatory) | Form D - Notice of Exempt Offering of Securities | NASDAQ:GOSS | Gossamer Bio Inc |
| 28/07/2023 | 21:46 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:GOSS | Gossamer Bio Inc |
| 24/07/2023 | 22:16 | Business Wire | Gossamer Bio to Hold Conference Call with PAH Experts to Discuss PROSERA Phase 3 Design and Interim TORREY OLE Results | NASDAQ:GOSS | Gossamer Bio Inc |
| 20/07/2023 | 13:56 | Business Wire | Gossamer Bio Announces $212 Million Private Placement Financing | NASDAQ:GOSS | Gossamer Bio Inc |